Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lyophilized fecal microbiota transplantation (University of British Columbia)
- Development stage
- Unknown
- Lead developer
- University of British Columbia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Lyophilized fecal microbiota transplantation (LYO-FMT) is a live biotherapeutic product being developed by the University of British Columbia for the treatment of active ulcerative colitis. [1] It is a freeze-dried preparation of stool from healthy, screened donors, which is administered to patients via oral capsules and enemas. [1] The treatment aims to restore a healthy gut microbiome, thereby reducing inflammation and inducing remission. [3, 5] A Phase 2 clinical trial (NCT04202211) was designed to evaluate the safety and efficacy of LYO-FMT for inducing remission in adults with active ulcerative colitis, though the protocol has been undergoing redesign. [1, 2]
- Other names
- fecal microbiota transplantfecal microbiota transplantation-University of British Columbia-ulcerative colitis
Beyond the preview
Go deeper on lyophilized fecal microbiota transplantation (University of British Columbia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lyophilized fecal microbiota transplantation (University of British Columbia).